What, exactly, is ‘gene therapy’? Commissioner Scott Gottlieb of the U.S. Food and Drug Administration's (‘FDA’s’) recently announced his agency's intent to develop an expedited approval pathway for ‘gene therapy’ despite the lack of any precise definition by regulators or scientists.1,2 At least 25 new therapeutic products have billed themselves as ‘gene therapies’, including several treatments—notably, adenovirus associated vectors (‘AAV’) and ex vivo T-cell therapies—that raise difficult questions as to the contours of the term.3,4,5 As of this writing, there are more than 700 active investigational new drug applications for ‘gene therapies’.6 And yet, FDA’s definition of ‘gene therapy’ dates back to 1993—ancient history relative to recent advances in the field.7,8